Literature DB >> 23963832

Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma.

Dong Yeob Shin1, Kwang Joon Kim, Cheol Ryong Ku, Mi Kyung Lee, Soo Il Jee, Woong Youn Chung, Eun Jig Lee.   

Abstract

Functional chemokine (C-X-C motif) receptor 4 (CXCR4) is well known to be over-expressed in papillary thyroid carcinoma (PTC). The aim of this study was to evaluate whether or not the expression of CXCR4 is different by histological subtypes of PTC and to elucidate the relationship between the expression of CXCR4 and clinicopathologic factors. CXCR4 expression in 127 PTC samples was assessed using immunohistochemical staining. The expression of CXCR4 showed different patterns according to the histological subtype of PTC (p < 0.001). A strong expression of CXCR4 was observed more frequently in the poorly differentiated region of PTC (81.0 %) than in classical PTC (50.0 %). Strong CXCR4 expression was less frequently shown in follicular variant (33.9 %) and in diffuse sclerosing variant (14.3 %) of PTC. CXCR4 expression showed a distinct pattern according to the histological subtype of PTC although not associated with other clinicopathological parameters.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23963832     DOI: 10.1007/s12022-013-9259-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  34 in total

1.  Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.

Authors:  Xin He; Qing Wei; Xia Zhang; Jiacheng Xiao; Xiaolong Jin; Yanbo Zhu; Bin Cui; Guang Ning
Journal:  Pathol Res Pract       Date:  2010-06-19       Impact factor: 3.250

Review 2.  Thyroid carcinoma.

Authors:  Steven I Sherman
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

Review 3.  New therapeutic approaches for metastatic thyroid carcinoma.

Authors:  Eric Baudin; Martin Schlumberger
Journal:  Lancet Oncol       Date:  2007-02       Impact factor: 41.316

Review 4.  Chemokines and cancer.

Authors:  Albert Zlotnik
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

5.  Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.

Authors:  Jamal Zidan; Drumea Karen; Moshe Stein; Edward Rosenblatt; Walid Basher; Abraham Kuten
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

6.  Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid.

Authors:  M Albareda; M Puig-Domingo; S Wengrowicz; J Soldevila; X Matias-Guiu; A Caballero; A Chico; A De Leiva
Journal:  Thyroid       Date:  1998-05       Impact factor: 6.568

Review 7.  The significance of cancer cell expression of the chemokine receptor CXCR4.

Authors:  Fran Balkwill
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

8.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

9.  The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma.

Authors:  Patrick L Wagner; Tracy-Ann Moo; Nimmi Arora; Yi-Fang Liu; Rasa Zarnegar; Theresa Scognamiglio; Thomas J Fahey
Journal:  Ann Surg Oncol       Date:  2008-08-12       Impact factor: 5.344

10.  Altered chemokine receptor expression in papillary thyroid cancer.

Authors:  Hernán E González; Andrea Leiva; Hugo Tobar; Karen Böhmwald; Grace Tapia; Javiera Torres; Lorena M Mosso; Susan M Bueno; Pablo Gonzalez; Alexis M Kalergis; Claudia A Riedel
Journal:  Thyroid       Date:  2009-09       Impact factor: 6.568

View more
  1 in total

Review 1.  Peptidomimetics as a new generation of antimicrobial agents: current progress.

Authors:  Patricia Méndez-Samperio
Journal:  Infect Drug Resist       Date:  2014-08-30       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.